Danesi R - Search Results

1

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.

Danesi R, Fogli S, Indraccolo S, Del Re M, Dei Tos AP, Leoncini L, Antonuzzo L, Bonanno L, Guarneri V, Pierini A, Amunni G, Conte P. Danesi R, et al. ESMO Open. 2021 Apr;6(2):100040. doi: 10.1016/j.esmoop.2020.100040. Epub 2021 Feb 2. ESMO Open. 2021. PMID: 33540286 Free PMC article. Review.

2

Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.

Falcone A, Pfanner E, Cianci C, Danesi R, Brunetti I, Del Tacca M, Conte PF. Falcone A, et al. Among authors: danesi r. Cancer. 1995 Jan 15;75(2):440-3. doi: 10.1002/1097-0142(19950115)75:2<440::aid-cncr2820750205>3.0.co;2-3. Cancer. 1995. PMID: 7812913 Clinical Trial.

3

Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks.

Andreuccetti M, Allegrini G, Antonuzzo A, Malvaldi G, Conte PF, Danesi R, Del Tacca M, Falcone A. Andreuccetti M, et al. Among authors: danesi r. Eur J Cancer. 1996 Jun;32A(7):1219-26. doi: 10.1016/0959-8049(96)00018-4. Eur J Cancer. 1996. PMID: 8758257

4

Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine.

Danesi R, Falcone A, Conte PF, Del Tacca M. Danesi R, et al. Clin Pharmacokinet. 1998 Feb;34(2):173-80. doi: 10.2165/00003088-199834020-00005. Clin Pharmacokinet. 1998. PMID: 9515187 Review.

5

Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo.

Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A, Fogli S, Del Tacca M. Bocci G, et al. Among authors: danesi r. Cancer Chemother Pharmacol. 1999;43(3):205-12. doi: 10.1007/s002800050885. Cancer Chemother Pharmacol. 1999. PMID: 9923550

6

Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens.

Innocenti F, Danesi R, Bocci G, Fogli S, Di Paolo A, Del Tacca M. Innocenti F, et al. Among authors: danesi r. Cancer Chemother Pharmacol. 1999;43(2):133-40. doi: 10.1007/s002800050873. Cancer Chemother Pharmacol. 1999. PMID: 9923818

7

An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma.

Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C, Del Tacca M. Fogli S, et al. Among authors: danesi r. Ther Drug Monit. 1999 Jun;21(3):367-75. doi: 10.1097/00007691-199906000-00022. Ther Drug Monit. 1999. PMID: 10365655 Clinical Trial.

8

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.

Falcone A, Antonuzzo A, Danesi R, Allegrini G, Monica L, Pfanner E, Masi G, Ricci S, Del Tacca M, Conte P. Falcone A, et al. Among authors: danesi r. Cancer. 1999 Aug 1;86(3):470-6. doi: 10.1002/(sici)1097-0142(19990801)86:3<470::aid-cncr15>3.0.co;2-7. Cancer. 1999. PMID: 10430255 Clinical Trial.

9

Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.

Danesi R, Conte PF, Del Tacca M. Danesi R, et al. Clin Pharmacokinet. 1999 Sep;37(3):195-211. doi: 10.2165/00003088-199937030-00002. Clin Pharmacokinet. 1999. PMID: 10511918 Review.

10

The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.

Gennari A, Donati S, Danesi R, Fogli S, Orlandini C, Del Tacca M, Conte PF. Gennari A, et al. Among authors: danesi r. Semin Oncol. 2000 Feb;27(1 Suppl 2):14-9. Semin Oncol. 2000. PMID: 10697031 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

526 results

Search Page

Filters